# Neomorph says it has closed a $100 million Series B round led by Deerfield Management.

*biotech · news · 2026-04-13 · TechStartups.com*

## Key points

- Neomorph closed a $100 million Series B round led by Deerfield Management with notable biotech investors.
- Neomorph's lead program, NEO-811, is now in a first-in-human Phase 1/2 trial for advanced kidney cancer.
- Pharma giants Novo Nordisk, Biogen, and AbbVie have partnered with Neomorph across multiple therapeutic areas.
- Neomorph's platform uses molecular glue degraders to target historically 'undruggable' disease-causing proteins.
- Upcoming clinical readouts from NEO-811 will be the first major tests of Neomorph's technology in patients.

**Companies:** Regeneron Pharmaceuticals, Biogen, AbbVie, Novo Nordisk, Neomorph
**Countries:** United States

[Read the full story on TechStartups.com](https://techstartups.com/2026/04/13/biotech-startup-neomorph-raises-100m-to-crack-the-undruggable-protein-problem-with-molecular-glue-technology/)

---

Canonical: https://newsio.io/n/456ecb16-cb7b-4296-a558-b74fd793730f/neomorph-says-it-has-closed-a-100-million-series-b-round-led-by-deerfield-manage
Summarized by Newsio from TechStartups.com. https://newsio.io/how-it-works